Latest news and press releases about Catalyst Pharmaceuticals, Inc. (CPRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders.
Price
| Price | $31.49 |
| Market Cap | $3.9B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 17.49 |
| Price / Book | 3.80 |
| EV / EBITDA | 9.27 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 23.65% |
| Return on Invested Capital | 19.67% |
| Return on Assets | 19.29% |
| Gross Margin | 82.32% |
| Operating Margin | 44.83% |
| Net Margin | 37.08% |
Related companies: AMLX · AXSM · EXEL · MDGL · TLPH · VKTX · VSTM
Explore sector: Healthcare · Biotechnology
More sections of CPRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks